Prostate Cancer Retreatment Trial Meets Safety Goals
The Re-LuPSMA study shows initial success in retreatment with lutetium Lu 177 vipivotide tetraxetan.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Do you believe the potential benefits of new cancer therapies justify their reported side effects?
A clinical trial at UCLA successfully met safety thresholds for retreating patients with metastatic castration-resistant prostate cancer using lutetium Lu 177 vipivotide tetraxetan. The study observed only two treatment-related serious adverse events, remaining well below the predefined stopping threshold of five.
Why it matters
This research aims to determine the safety and efficacy of providing additional cycles of radioligand therapy to patients who previously responded to the treatment. Establishing safety in retreatment could provide an ongoing therapeutic option for those fighting advanced prostate cancer.
The study recorded 165 total adverse effects among 19 patients, with 88 deemed possibly treatment-related. Reported side effects included 14 cases of lymphocytopenia, 11 of leukopenia, and 8 of anemia.
The players
UCLA
This major research university serves as the location for the Re-LuPSMA clinical trial.
ESMO Congress
This is an international meeting for oncology professionals where significant clinical trial results are presented.
The details
Patients enrolled in the study received between 4 and 6 cycles of initial therapy and achieved at least a 50% prostate-specific antigen decline prior to starting retreatment. Eligible participants undergo PSMA PET imaging before beginning the additional cycles of radioligand therapy, which averaged a median of 3 cycles per patient.
Timeline
July 2026: FDA approval for lutetium Lu 177 vipivotide tetraxetan in hormone-sensitive cancer.
October 24, 2026: Interim safety data presented at the ESMO Congress.
Health Landscape
The Re-LuPSMA clinical trial provides a framework for evaluating the safety of repeated doses of radioligand therapy in oncology patients. This study marks a shift toward determining how long patients can safely continue specific life-extending cancer treatments.
The results suggest that select patients may be able to safely undergo additional rounds of radioligand therapy after their initial treatment course. Patients should discuss potential eligibility for retreatment and associated side effect risks with their oncology team.
The takeaway
This trial demonstrates that retreatment protocols for prostate cancer can potentially remain within safe adverse-event thresholds. Future research into treatment holidays and extended cycles will further clarify how patients can maximize the benefits of this therapy.
Further reading
Learn more about the latest research in the Cancer section.
More information
View the Re-LuPSMA clinical trial study details on the official government portal.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe the potential benefits of new cancer therapies justify their reported side effects?
